RARE DISEASE
KCNQ2-related epileptic encephalopathy
KCNQ2-related epileptic encephalopathy
KCNQ2-related epileptic encephalopathy
Synonyms: KCNQ2-NEE, KCNQ2-related neonatal epileptic encephalopathy
Synonyms: KCNQ2-NEE, KCNQ2-related neonatal epileptic encephalopathy
Synonyms: KCNQ2-NEE, KCNQ2-related neonatal epileptic encephalopathy
Drug discovery
3
drugs
With orphan designations
Overview
KCNQ2-related epileptic encephalopathy is a genetic disorder caused by pathogenic variants in the KCNQ2 gene, disrupting potassium channel function and leading to neuronal hyperexcitability. It manifests in neonates (typically within the first week of life) with focal tonic seizures, burst-suppression EEG patterns, and developmental delays. Severity ranges from self-limited neonatal epilepsy to refractory developmental and epileptic encephalopathy (DEE), often accompanied by intellectual disability, hypotonia, and autism spectrum features [1][2][6][11][19].
Key Clinical Insights:
Burden
Persistent neurodevelopmental impairment (79% with moderate-to-severe intellectual disability), cortical visual impairment, and autism in >50% [4][16][19].
High healthcare utilization: Frequent hospitalizations, polypharmacy, and lifelong multidisciplinary care [4][16].
Mortality: ~50% mortality in infancy for severe DEE; survivors often require lifelong assistance [12][17].
Sodium channel blockers and ketogenic diet may improve seizure control, but neurodevelopmental deficits typically persist, underscoring the need for precision therapies targeting Kv7.2 channels [6][14][18].
Therapies
First-line: Sodium channel blockers (carbamazepine, phenytoin) show efficacy in 73% of cases [8][13].
Adjuncts: Ketogenic diet (notable in refractory cases), topiramate, levetiracetam, vagus nerve stimulation, and rescue therapies for seizure clusters [3][2][12].
Developmental support: Early intervention with physical, occupational, and speech therapy [2][17].
Categories: rare genetic diseases, rare neurological diseases
Research Papers
71 drug discovery papers about KCNQ2-related epileptic encephalopathy, with 7 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
71 drug discovery papers about KCNQ2-related epileptic encephalopathy, with 7 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
categories:
Small molecules
small molecules
2026-09-22 | Potassium Channel-Related Developmental and Epileptic Encephalopathies: From Functional Mechanisms to Precision Therapeutics — A Narrative Review Focused on KCNQ2, KCNA2, KCNT1, and KCNB1
Potassium channels are central regulators of neuronal resting membrane potential, action-potential repolarization, firing adaptation, and neurotransmitter release. Pathogenic variants in potassium-channel genes can produce a broad neurodevelopmental spectrum, ranging from self-limited epilepsy to severe developmental and epileptic encephalopathies (DEEs). Importantly, the direction of channel dysfunction cannot be inferred reliably from the clinical phenotype alone: loss-of-function, gain-of-function, dominant-negative, and mixed effects may converge on epilepsy through cell-type- and circuit-specific mechanisms. This narrative review examines four potassium channelopathies especially relevant to pediatric DEE and precision neurology—KCNQ2, KCNA2, KCNT1, and KCNB1. We integrate electroclinical phenotypes, functional mechanisms, genotype-phenotype correlations, conventional antiseizure treatment, and emerging mechanism-based therapies. KCNQ2 illustrates the clinical value of early molecular diagnosis, with sodium-channel blockers showing high effectiveness in loss-of-function neonatal epilepsies and recent multicenter data associating earlier treatment with earlier seizure offset and more favorable developmental trajectories. KCNA2 demonstrates the need for functional stratification because gain-of-function variants may respond to 4-aminopyridine. KCNT1-related epilepsy remains therapeutically challenging; quinidine has inconsistent clinical effectiveness, while antisense oligonucleotide strategies are supported by preclinical studies. KCNB1-related disorders combine epilepsy with prominent cognitive, language, and behavioral morbidity and currently lack a validated gene-specific therapy. Across these disorders, functional testing, natural-history cohorts, patient-centered outcomes, and trial-ready registries are essential for moving from gene diagnosis to disease modification. Potassium channelopathies provide a model for precision medicine in pediatric neurology in which treatment selection should increasingly integrate phenotype, variant mechanism, developmental timing, and evidence level rather than gene name alone.
2026-06-13 | Assessment of gabapentin efficacy in patients with KCNQ2-developmental epileptic encephalopathy.
KCNQ2‑related developmental epileptic encephalopathy (KCNQ2‑DEE) is characterized by intractable epilepsy, cognitive impairment, and behavioral problems, highlighting the urgent need for precision therapies. This study aimed to promote the clinical application of gabapentin, a known Kv7 channel opener, in KCNQ2‑DEE by evaluating its efficacy in four patients carrying different KCNQ2 variants. Three patients with S6‑segment variants (p.A294V, p.F305I, p.F305del) showed clinical improvement in both seizure control and cognition following add‑on gabapentin. In contrast, the patient with the S4 variant p.L200P did not exhibit electroencephalographic improvement, although some developmental progress was noted. Functional analysis in homomeric expression systems revealed that the three S6 variants produced negligible currents, consistent with severe loss‑of‑function (LoF). The p.L200P variant, however, showed smaller currents than wild‑type (WT) at voltages below + 20 mV, larger currents at higher voltages, slower activation kinetics, and a depolarized shift in half‑activation voltage (V₁/₂), indicating a mixed LoF/gain‑of‑function phenotype. In heteromeric Kv7.2/Kv7.3 channels, p.L200P retained significantly higher current compared to the S6 variants, which may explain the poorer response to gabapentin in this patient. Together, these findings further support gabapentin as a potential precision therapy for a subset of KCNQ2‑DEE patients, addressing an unmet clinical need.
2026-06-01 | Navigating the complexities of dual CNV findings: a case of DEE7 caused by a de novo KCNQ2 deletion and a Co-occurring chromosome 13 duplication - a case report and literature review.
Developmental and epileptic encephalopathy 7 (DEE7) is a severe neurodevelopmental disorder stemming from mutations in the KCNQ2 gene, which encodes a critical voltage-gated potassium channel subunit. While KCNQ2 mutations are known to cause a spectrum of diseases, from benign familial neonatal seizures (BFNS1) to drug-resistant DEE7, the clinical outcomes specifically associated with large deletions-a rare mechanism causing haploinsufficiency-are not well defined. This study reports a de novo KCNQ2 large deletion and aims to delineate the associated clinical trajectory and treatment response. We report a 1 year 5 months female who presented with frequent seizures starting in the neonatal period (7 days after birth), characterized by limb stiffness and facial cyanosis, with a frequency of 4-5 episodes per week. Initial neurological examination revealed no focal deficits, and brain MRI showed no structural abnormalities. However, electroencephalography demonstrated slowed background activity with multifocal epileptiform discharges. Standardized neurodevelopmental assessments confirmed severe global delay (Griffiths Developmental Quotient of 60 and Alberta Infant Motor Scale score below the 5th percentile at 3 months of age). Trio-based whole-exome sequencing was performed, identifying a ∼1.62 Mb de novo heterozygous deletion at chromosome 20q13.33 and a co-occurring ∼4.68 Mb duplication at chromosome 13q34 in the proband. This variant was classified as pathogenic according to American College of Medical Genetics and Genomics (ACMG) guidelines and fully encompassed the KCNQ2 gene, leading to a definitive diagnosis of KCNQ2-related developmental and epileptic encephalopathy 7 (DEE7). We diagnosed DEE7 caused by a large KCNQ2 deletion using trio whole-exome sequencing and multiplex ligation-dependent probe amplification (MLPA). Despite the severe genotype, early targeted treatment led to complete seizure freedom and modest neurodevelopmental progress. This case demonstrates that seizure freedom and some developmental gains are achievable, highlighting the potential benefit of early intervention even in patients with severe genotypes and underscoring the need for copy number variation (CNV) analysis in epilepsy genetic testing.
2026-02-25 | Kcnq2 R213 knock-in mice reveal variant- and region-specific mechanisms underlying self-limited familial neonatal-infantile epilepsy and early infantile developmental and epileptic encephalopathy
Abstract KCNQ2 variants cause a spectrum of neonatal epilepsies, ranging from self-limited familial neonatal-infantile epilepsy (SeLFNIE) to early infantile developmental and epileptic encephalopathy (EIDEE). Two distinct missense variants at the same residue, p.R213W and p.R213Q, are associated with SeLFNIE and EIDEE, respectively. This study aimed to elucidate the in vivo effects of these variants on brain development and neuronal excitability using two knock-in mouse models, Kcnq2R213W/+ and Kcnq2R213Q/+. We assessed survival, seizure susceptibility, histological and molecular phenotypes, and electrophysiological properties in cortical and hippocampal neurons, and conducted RNA sequencing analyses of cortical tissue to identify transcriptional alterations. Kcnq2R213Q/+ mice exhibited tonic–clonic seizures, shortened lifespan, delayed cortical neuron migration, abnormal elongation of the axon initial segment in cortical neurons, and dentate gyrus-specific gliosis. In contrast, Kcnq2R213W/+ mice showed a milder phenotype with transient seizures and largely preserved cortical function. RNA sequencing analyses revealed that p.R213Q selectively upregulated genes involved in endoplasmic reticulum stress and synaptic regulation, together with compensatory upregulation of potassium channel subunits. These findings demonstrate that the two Kcnq2 variants lead to distinct neurodevelopmental phenotypes, attributable not only to differential impairment of the M-current but also to aberrant cortical development and stress response pathways. In particular, p.R213Q induces sustained cortical hyperexcitability and axon initial segment abnormalities, whereas p.R213W results in the milder phenotype. The established knock-in models provide powerful tools for elucidating disease mechanisms of EIDEE and SeLFNIE, and developing targeted therapies for KCNQ2-related epilepsies.
2026-01-24 | Integrated genotype-phenotype function analysis reveals distinct pathogenic mechanisms for cognitive impairment in KCNQ2-related disorders.
Pathogenic variants of KCNQ2 lead to a spectrum of disorders including self-limited familial neonatal-infantile epilepsy (SeL(F)NIE), developmental and epileptic encephalopathies (DEEs), and neurodevelopmental disorders (NDDs) with intellectual disability (ID). This study aimed to delineate the clinical progression and underlying pathogenesis of these disorders. Particularly, we unraveled the role of gain-of-function (GoF) variants in neurodevelopmental impairment. We conducted a longitudinal study of a 90-patient Chinese cohort with KCNQ2-related disorders, classified into SeL(F)NIE, DEEs, and NDDs subgroups. Clinical phenotyping was integrated with functional analyses (electrophysiology, biochemistry) of five missense variants in homomeric and heteromeric (with Kv7.3/Kv7.5) channel assemblies. Despite comparable seizure control to SeL(F)NIE (96% vs 100%), the NDDs group exhibited significant cognitive impairment. All deceased patients (8/90) were in the DEEs group. Functional profiling revealed a spectrum from loss-of-function (LoF) to GoF. LoF variants (e.g., S247L in DEEs) were linked to severe epilepsy. Crucially, we identified strong GoF variants (P335A/L in NDDs) in the S6-HelixA domain that confer insensitivity to phosphatidylinositol 4,5-bisphosphate (PIP2) regulation and are associated with a primary neurodevelopmental phenotype, distinct from the severe epileptic phenotype of established voltage-sensing domain (VSD) GoF variants. Our integrated clinical and functional analysis showed that the clinical outcome relies on the functional consequence of a KCNQ2 variant (LoF vs GoF) and its behavior in heteromeric complexes, rather than its mere location. We defined a novel class of strong GoF KCNQ2 variants that are mechanistically and phenotypically distinct, highlighting aberrantly enhanced channel function as a key driver of cognitive dysfunction and presenting new targets for precision medicine.
small molecules
2026-09-22 | Potassium Channel-Related Developmental and Epileptic Encephalopathies: From Functional Mechanisms to Precision Therapeutics — A Narrative Review Focused on KCNQ2, KCNA2, KCNT1, and KCNB1
Potassium channels are central regulators of neuronal resting membrane potential, action-potential repolarization, firing adaptation, and neurotransmitter release. Pathogenic variants in potassium-channel genes can produce a broad neurodevelopmental spectrum, ranging from self-limited epilepsy to severe developmental and epileptic encephalopathies (DEEs). Importantly, the direction of channel dysfunction cannot be inferred reliably from the clinical phenotype alone: loss-of-function, gain-of-function, dominant-negative, and mixed effects may converge on epilepsy through cell-type- and circuit-specific mechanisms. This narrative review examines four potassium channelopathies especially relevant to pediatric DEE and precision neurology—KCNQ2, KCNA2, KCNT1, and KCNB1. We integrate electroclinical phenotypes, functional mechanisms, genotype-phenotype correlations, conventional antiseizure treatment, and emerging mechanism-based therapies. KCNQ2 illustrates the clinical value of early molecular diagnosis, with sodium-channel blockers showing high effectiveness in loss-of-function neonatal epilepsies and recent multicenter data associating earlier treatment with earlier seizure offset and more favorable developmental trajectories. KCNA2 demonstrates the need for functional stratification because gain-of-function variants may respond to 4-aminopyridine. KCNT1-related epilepsy remains therapeutically challenging; quinidine has inconsistent clinical effectiveness, while antisense oligonucleotide strategies are supported by preclinical studies. KCNB1-related disorders combine epilepsy with prominent cognitive, language, and behavioral morbidity and currently lack a validated gene-specific therapy. Across these disorders, functional testing, natural-history cohorts, patient-centered outcomes, and trial-ready registries are essential for moving from gene diagnosis to disease modification. Potassium channelopathies provide a model for precision medicine in pediatric neurology in which treatment selection should increasingly integrate phenotype, variant mechanism, developmental timing, and evidence level rather than gene name alone.
2026-06-13 | Assessment of gabapentin efficacy in patients with KCNQ2-developmental epileptic encephalopathy.
KCNQ2‑related developmental epileptic encephalopathy (KCNQ2‑DEE) is characterized by intractable epilepsy, cognitive impairment, and behavioral problems, highlighting the urgent need for precision therapies. This study aimed to promote the clinical application of gabapentin, a known Kv7 channel opener, in KCNQ2‑DEE by evaluating its efficacy in four patients carrying different KCNQ2 variants. Three patients with S6‑segment variants (p.A294V, p.F305I, p.F305del) showed clinical improvement in both seizure control and cognition following add‑on gabapentin. In contrast, the patient with the S4 variant p.L200P did not exhibit electroencephalographic improvement, although some developmental progress was noted. Functional analysis in homomeric expression systems revealed that the three S6 variants produced negligible currents, consistent with severe loss‑of‑function (LoF). The p.L200P variant, however, showed smaller currents than wild‑type (WT) at voltages below + 20 mV, larger currents at higher voltages, slower activation kinetics, and a depolarized shift in half‑activation voltage (V₁/₂), indicating a mixed LoF/gain‑of‑function phenotype. In heteromeric Kv7.2/Kv7.3 channels, p.L200P retained significantly higher current compared to the S6 variants, which may explain the poorer response to gabapentin in this patient. Together, these findings further support gabapentin as a potential precision therapy for a subset of KCNQ2‑DEE patients, addressing an unmet clinical need.
2026-06-01 | Navigating the complexities of dual CNV findings: a case of DEE7 caused by a de novo KCNQ2 deletion and a Co-occurring chromosome 13 duplication - a case report and literature review.
Developmental and epileptic encephalopathy 7 (DEE7) is a severe neurodevelopmental disorder stemming from mutations in the KCNQ2 gene, which encodes a critical voltage-gated potassium channel subunit. While KCNQ2 mutations are known to cause a spectrum of diseases, from benign familial neonatal seizures (BFNS1) to drug-resistant DEE7, the clinical outcomes specifically associated with large deletions-a rare mechanism causing haploinsufficiency-are not well defined. This study reports a de novo KCNQ2 large deletion and aims to delineate the associated clinical trajectory and treatment response. We report a 1 year 5 months female who presented with frequent seizures starting in the neonatal period (7 days after birth), characterized by limb stiffness and facial cyanosis, with a frequency of 4-5 episodes per week. Initial neurological examination revealed no focal deficits, and brain MRI showed no structural abnormalities. However, electroencephalography demonstrated slowed background activity with multifocal epileptiform discharges. Standardized neurodevelopmental assessments confirmed severe global delay (Griffiths Developmental Quotient of 60 and Alberta Infant Motor Scale score below the 5th percentile at 3 months of age). Trio-based whole-exome sequencing was performed, identifying a ∼1.62 Mb de novo heterozygous deletion at chromosome 20q13.33 and a co-occurring ∼4.68 Mb duplication at chromosome 13q34 in the proband. This variant was classified as pathogenic according to American College of Medical Genetics and Genomics (ACMG) guidelines and fully encompassed the KCNQ2 gene, leading to a definitive diagnosis of KCNQ2-related developmental and epileptic encephalopathy 7 (DEE7). We diagnosed DEE7 caused by a large KCNQ2 deletion using trio whole-exome sequencing and multiplex ligation-dependent probe amplification (MLPA). Despite the severe genotype, early targeted treatment led to complete seizure freedom and modest neurodevelopmental progress. This case demonstrates that seizure freedom and some developmental gains are achievable, highlighting the potential benefit of early intervention even in patients with severe genotypes and underscoring the need for copy number variation (CNV) analysis in epilepsy genetic testing.
2026-02-25 | Kcnq2 R213 knock-in mice reveal variant- and region-specific mechanisms underlying self-limited familial neonatal-infantile epilepsy and early infantile developmental and epileptic encephalopathy
Abstract KCNQ2 variants cause a spectrum of neonatal epilepsies, ranging from self-limited familial neonatal-infantile epilepsy (SeLFNIE) to early infantile developmental and epileptic encephalopathy (EIDEE). Two distinct missense variants at the same residue, p.R213W and p.R213Q, are associated with SeLFNIE and EIDEE, respectively. This study aimed to elucidate the in vivo effects of these variants on brain development and neuronal excitability using two knock-in mouse models, Kcnq2R213W/+ and Kcnq2R213Q/+. We assessed survival, seizure susceptibility, histological and molecular phenotypes, and electrophysiological properties in cortical and hippocampal neurons, and conducted RNA sequencing analyses of cortical tissue to identify transcriptional alterations. Kcnq2R213Q/+ mice exhibited tonic–clonic seizures, shortened lifespan, delayed cortical neuron migration, abnormal elongation of the axon initial segment in cortical neurons, and dentate gyrus-specific gliosis. In contrast, Kcnq2R213W/+ mice showed a milder phenotype with transient seizures and largely preserved cortical function. RNA sequencing analyses revealed that p.R213Q selectively upregulated genes involved in endoplasmic reticulum stress and synaptic regulation, together with compensatory upregulation of potassium channel subunits. These findings demonstrate that the two Kcnq2 variants lead to distinct neurodevelopmental phenotypes, attributable not only to differential impairment of the M-current but also to aberrant cortical development and stress response pathways. In particular, p.R213Q induces sustained cortical hyperexcitability and axon initial segment abnormalities, whereas p.R213W results in the milder phenotype. The established knock-in models provide powerful tools for elucidating disease mechanisms of EIDEE and SeLFNIE, and developing targeted therapies for KCNQ2-related epilepsies.
2026-01-24 | Integrated genotype-phenotype function analysis reveals distinct pathogenic mechanisms for cognitive impairment in KCNQ2-related disorders.
Pathogenic variants of KCNQ2 lead to a spectrum of disorders including self-limited familial neonatal-infantile epilepsy (SeL(F)NIE), developmental and epileptic encephalopathies (DEEs), and neurodevelopmental disorders (NDDs) with intellectual disability (ID). This study aimed to delineate the clinical progression and underlying pathogenesis of these disorders. Particularly, we unraveled the role of gain-of-function (GoF) variants in neurodevelopmental impairment. We conducted a longitudinal study of a 90-patient Chinese cohort with KCNQ2-related disorders, classified into SeL(F)NIE, DEEs, and NDDs subgroups. Clinical phenotyping was integrated with functional analyses (electrophysiology, biochemistry) of five missense variants in homomeric and heteromeric (with Kv7.3/Kv7.5) channel assemblies. Despite comparable seizure control to SeL(F)NIE (96% vs 100%), the NDDs group exhibited significant cognitive impairment. All deceased patients (8/90) were in the DEEs group. Functional profiling revealed a spectrum from loss-of-function (LoF) to GoF. LoF variants (e.g., S247L in DEEs) were linked to severe epilepsy. Crucially, we identified strong GoF variants (P335A/L in NDDs) in the S6-HelixA domain that confer insensitivity to phosphatidylinositol 4,5-bisphosphate (PIP2) regulation and are associated with a primary neurodevelopmental phenotype, distinct from the severe epileptic phenotype of established voltage-sensing domain (VSD) GoF variants. Our integrated clinical and functional analysis showed that the clinical outcome relies on the functional consequence of a KCNQ2 variant (LoF vs GoF) and its behavior in heteromeric complexes, rather than its mere location. We defined a novel class of strong GoF KCNQ2 variants that are mechanistically and phenotypically distinct, highlighting aberrantly enhanced channel function as a key driver of cognitive dysfunction and presenting new targets for precision medicine.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
3 orphan drug designations for KCNQ2-related epileptic encephalopathy.
3 orphan drug designations for KCNQ2-related epileptic encephalopathy.
Drug | Therapy type | Orphan designation | Clinical trial status | Sponsor |
|---|---|---|---|---|
replication deficient adeno-associated virus gene therapy vector expressing a FRRS1L gene | gene therapies | FDA | — | Finding Hope for FRRS1L |
Retigabine | small molecules | EMA | FGK Representative Service GmbH | |
ezogabine | small molecules | FDA | Xenon Pharmaceuticals, Inc. |
“Terminated” – programs with discontinued clinical trials, or with no updates reported for 5 years after completion or 12 years after the last trial started.
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI’s forecasts to outperform average preclinical success rates. Whether you’re expanding your R&D pipeline, evaluating a partnership, or simply have a question — we’d love to hear from you.